Why is Bal Pharma Ltd ?
1
Weak Long Term Fundamental Strength with an average Return on Capital Employed (ROCE) of 9.02%
- Poor long term growth as Net Sales has grown by an annual rate of 5.20% over the last 5 years
- Low ability to service debt as the company has a high Debt to EBITDA ratio of 4.69 times
2
Positive results in Sep 26
- PAT(Latest six months) At Rs 2.54 cr has Grown at 179.12%
- OPERATING CF(Y) Highest at Rs 30.84 Cr
- NET SALES(Q) Highest at Rs 89.95 cr
3
Stock is technically in a Mildly Bullish range
- The technical trend has improved from Sideways on 02-Nov-26
- A key technical factor - OBV has been Bullish since 02 Nov 2026
4
With ROCE of 9.6, it has a Very Attractive valuation with a 1.2 Enterprise value to Capital Employed
- The stock is trading at a discount compared to its peers' average historical valuations
- Over the past year, while the stock has generated a return of 7.76%, its profits have risen by 16% ; the PEG ratio of the company is 1.1
5
Majority shareholders : Promoters
How much should you hold?
- Overall Portfolio exposure to Bal Pharma should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Bal Pharma for you?
High Risk, Medium Return
Absolute
Risk Adjusted
Volatility
Bal Pharma
7.76%
0.15
52.80%
Sensex
-2.0%
-0.13
14.98%
Quality key factors
Factor
Value
Sales Growth (5y)
5.20%
EBIT Growth (5y)
8.41%
EBIT to Interest (avg)
1.23
Debt to EBITDA (avg)
4.84
Net Debt to Equity (avg)
1.91
Sales to Capital Employed (avg)
1.49
Tax Ratio
1.36%
Dividend Payout Ratio
30.40%
Pledged Shares
0
Institutional Holding
0.28%
ROCE (avg)
9.58%
ROE (avg)
7.82%
Valuation Key Factors 
Factor
Value
P/E Ratio
17
Industry P/E
40
Price to Book Value
1.53
EV to EBIT
12.32
EV to EBITDA
8.14
EV to Capital Employed
1.18
EV to Sales
0.85
PEG Ratio
1.05
Dividend Yield
1.44%
ROCE (Latest)
9.60%
ROE (Latest)
9.11%
Loading Valuation Snapshot...
Technical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bearish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Mildly Bullish
Dow Theory
Mildly Bullish
No Trend
OBV
No Trend
Bullish
Technical Movement
10What is working for the Company
PAT(Latest six months)
At Rs 2.54 cr has Grown at 179.12%
OPERATING CF(Y)
Highest at Rs 30.84 Cr
NET SALES(Q)
Highest at Rs 89.95 cr
-2What is not working for the Company
INTEREST(Q)
Highest at Rs 4.98 cr
NON-OPERATING INCOME(Q)
is 84.46 % of Profit Before Tax (PBT
Loading Valuation Snapshot...
Here's what is working for Bal Pharma
Profit After Tax (PAT) - Latest six months
At Rs 2.54 cr has Grown at 179.12%
Year on Year (YoY)MOJO Watch
PAT trend is very positive
PAT (Rs Cr)
Operating Cash Flow - Annually
Highest at Rs 30.84 Cr
in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (Rs Cr)
Net Sales - Quarterly
Highest at Rs 89.95 cr
in the last five quartersMOJO Watch
Near term sales trend is positive
Net Sales (Rs Cr)
Net Sales - Quarterly
At Rs 89.95 cr has Grown at 21.52%
Year on Year (YoY)MOJO Watch
Near term sales trend is positive
Net Sales (Rs Cr)
Here's what is not working for Bal Pharma
Interest - Quarterly
Highest at Rs 4.98 cr
in the last five quarters and Increased by 11.41 % (QoQ)MOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (Rs cr)
Non Operating Income - Quarterly
is 84.46 % of Profit Before Tax (PBT)
MOJO Watch
The company's income from non business activities is high; which is not a sustainable business model
Non Operating Income to PBT
Non Operating Income - Quarterly
Highest at Rs 1.63 cr
in the last five quartersMOJO Watch
Increased income from non business activities may not be sustainable
Non Operating Income